Related Experiment Video
Updated: May 10, 2025

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Partial areas under the curve of the cumulative distribution function as a new composite estimand for randomized
Masataka Taguri1,2, Kenichi Hayashi3
1Department of Health Data Science, Tokyo Medical University, Japan.
Abstract:
Clinical trials often face the challenge of post-randomization events, such as the initiation of rescue therapy or the premature discontinuation of randomized treatment. Such events, called "intercurrent events" (ICEs) in ICH E9(R1), may influence the estimation and interpretation of treatment effects. According to ICH E9(R1), there are five strategies for handling ICEs. This study focuses on the composite strategy, which incorporates ICEs in the outcome of interest and defines the treatment effects using composite endpoints that combine the measured continuous variables and ICEs. An advantage of this strategy is that it avoids the occurrence of missing data because they are defined as part of the outcome of interest. In this study, we propose a new composite estimand: the difference in the partial areas under the curves (pAUCs) of the cumulative distribution function. While the pAUC is closely related to the trimmed mean approach proposed by Permutt and Li, it offers the advantage of allowing pre-specification of the cutoff value for a "good" response based on clinical considerations. This ensures that the pAUC can be calculated irrespective of the proportion of ICEs. We describe the causal interpretation of our method and its relationship with two other strategies (treatment policy and hypothetical strategies) using a potential outcome framework. We present simulation results in which our method performs reasonably well compared to several existing approaches in terms of type I error, power, and the proportion of undefined test statistics.
More Related Videos
10:33Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
Published on: September 4, 2017
11:38High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
Published on: May 10, 2016
Related Concept Videos
Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
Kaplan-Meier Approach
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Analysis of Population Pharmacokinetic Data
Two-Compartment Open Model: Extravascular Administration
The absorption exponent (ka) indicates the speed at which the drug...